Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Risk “Concept Papers” Expected In March; April Workshop Set

Executive Summary

FDA hopes to release three "concept papers" on risk assessment and risk management March 10 as the first step in developing risk guidances mandated under the Prescription Drug User Fee Act reauthorization

You may also be interested in...



PhRMA Wants Clearer Definition Of Safety “Signal”; FDA Proposes Newsletter

FDA's upcoming pharmacovigilance guidance should include a clearer definition of what constitutes a drug risk "signal," the Pharmaceutical Research & Manufacturers of America maintains

PhRMA Wants Clearer Definition Of Safety “Signal”; FDA Proposes Newsletter

FDA's upcoming pharmacovigilance guidance should include a clearer definition of what constitutes a drug risk "signal," the Pharmaceutical Research & Manufacturers of America maintains

Rx Name Risk Assessments Should Be Conducted By Manufacturers, FDA Says

Drug and biologic sponsors should conduct a risk assessment on the product's name, labeling and packaging to minimize medication errors, an FDA concept paper states

Related Content

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel